Skip to main content
Boule Diagnostics logo

Boule Diagnostics — Investor Relations & Filings

Ticker · BOUL ISIN · SE0011231158 LEI · 213800IK1TGY858TKZ45 ST Manufacturing
Open in API
Filings indexed 223 across all filing types
Latest filing 2017-05-01 Interim / Quarterly Rep…
Country SE Sweden
Listing ST BOUL

About Boule Diagnostics

https://boule.com/

Boule Diagnostics is a global provider of diagnostic solutions specializing in hematology. The company develops, manufactures, and markets systems and consumables for blood diagnostics, including hematology analyzers, clinical chemistry analyzers, and associated reagents, controls, and calibrators. Its products are tailored for decentralized healthcare settings in both the human and veterinary markets, such as smaller laboratories and clinics. The company aims to enhance global healthcare access by providing high-quality instruments that deliver timely and accurate blood test results.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for Boule Diagnostics AB for the period January–March 2017. It contains comprehensive financial statements, including income statements, balance sheets, cash flow analysis, and detailed management commentary on business performance, regional sales, and market outlook. It is not an announcement of a report, but the report itself, containing substantive financial data. Q1 2017
2017-05-01 Swedish
Annual Report 2016
Annual Report Classification · 1% confidence The document is titled 'Årsredovisning 2016' (Annual Report 2016) for Boule Diagnostics AB. It contains comprehensive sections including a strategic overview, financial goals, management review (VD har ordet), financial statements, notes, and an audit report (Revisionsberättelse). As it is the full annual report containing substantive financial data and analysis for the fiscal year, it is classified as an Annual Report (10-K). FY 2016
2017-04-20 Swedish
Boule Diagnostics vinner strategisk upphandling
Legal Proceedings Report Classification · 1% confidence The document is a short announcement dated March 17, 2017, detailing a strategic procurement win by Boule Diagnostics AB for hematology instruments from the Västra Götaland region. It includes a quote from the CEO and concludes with a statement that the information is required to be made public under the EU Market Abuse Regulation (MAR) and was released at a specific time. This format—a brief, time-sensitive announcement of a significant event (a contract win) intended for immediate public disclosure under regulatory requirements—most closely aligns with a general regulatory announcement or filing that doesn't fit the specific financial report categories (like 10-K, ER, IR). Since it is a specific, non-financial regulatory disclosure, the most appropriate general category is Regulatory Filings (RNS), as it is not a dividend notice, director dealing, or capital change, but rather a material event disclosure.
2017-03-17 Swedish
Rättelse om tidigare kommunicerad utdelning i Boule Diagnostics AB
Notice of Dividend Amount Classification · 1% confidence The document is titled "Rättelse om tidigare kommunicerad utdelning i Boule Diagnostics AB" (Correction regarding previously communicated dividend in Boule Diagnostics AB). It explicitly corrects a previously announced dividend amount (SEK 1.25 changed to SEK 1.40 per share for 2016). This is a direct announcement detailing the proposed dividend amount, which aligns perfectly with the definition for 'Notice of Dividend Amount' (DIV). Although it is a correction, the core subject matter is the dividend proposal itself, not the general release of a report (RPA) or a general regulatory filing (RNS). The length is short, but the content is specific to the dividend amount.
2017-02-16 Swedish
Earnings Release 2016
Earnings Release Classification · 1% confidence The document text explicitly contains the title "BOULE DIAGNOSTICS BOKSLUTSKOMMUNIKÉ 1 JANUARI – 31 DECEMBER 2016" multiple times, which translates to 'Year-end report' or 'Full-year financial report'. It provides detailed financial figures for the fourth quarter (October-December 2016) and the full year (January-December 2016), including revenue, operating profit, net result, cash flow, and balance sheet items. This comprehensive reporting structure for a full fiscal year strongly indicates an Annual Report, which corresponds to the 10-K filing type in the US context, or the closest equivalent for comprehensive annual financial disclosure. Although the Swedish term 'Bokslutskommuniké' often precedes the formal 10-K/Annual Report filing, given the depth of the financial data presented (covering the entire year and including management commentary and detailed tables), it functions as the primary annual financial disclosure document. Q4 2016
2017-02-16 Swedish
Boule Diagnostics presenterar nya finansiella mål och utdelningspolicy
Notice of Dividend Amount Classification · 1% confidence The document text announces revisions to the company's financial targets (EBIT margin, sales growth, net debt) and an adjustment to the dividend policy (payout ratio). This content directly relates to future financial guidance and capital allocation strategy. While it touches upon dividends (DIV), the primary focus is on setting new long-term financial goals and capital structure parameters. This type of strategic financial update, which is not a formal earnings release (ER) or a comprehensive interim report (IR), fits best under Capital/Financing Update (CAP) as it directly impacts capital structure goals and future financing expectations, or potentially as a general Regulatory Filing (RNS) if no better fit exists. However, since it explicitly details new financial targets and dividend policy adjustments, it is most closely aligned with updates concerning capital structure and financial outlook, making 'CAP' a strong candidate, although 'RNS' is often used for such specific, non-standard announcements. Given the content focuses heavily on financial goals and dividend policy, which are core elements of capital management, I will classify it as CAP. The document is short and appears to be a formal announcement required under market abuse regulations, but the substance is financial targets/policy.
2017-02-15 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.